Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average Price Target from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average recommendation of “Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $20.83.

Several analysts have recently commented on STOK shares. Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, September 11th.

Stoke Therapeutics Trading Down 1.2 %

Shares of Stoke Therapeutics stock opened at $11.91 on Wednesday. The company has a market cap of $620.76 million, a P/E ratio of -4.94 and a beta of 0.97. The business has a 50-day moving average price of $13.48 and a two-hundred day moving average price of $13.69. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The business had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. Equities research analysts forecast that Stoke Therapeutics will post -2.1 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. bought a new position in shares of Stoke Therapeutics during the second quarter valued at about $19,835,000. SG Americas Securities LLC lifted its position in shares of Stoke Therapeutics by 610.3% during the 2nd quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after buying an additional 58,943 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $1,224,000. Vanguard Group Inc. grew its holdings in shares of Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after acquiring an additional 67,052 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.